scispace - formally typeset
R

Robert C. Bast

Researcher at University of Texas MD Anderson Cancer Center

Publications -  669
Citations -  71463

Robert C. Bast is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 119, co-authored 654 publications receiving 65719 citations. Previous affiliations of Robert C. Bast include University of California, San Francisco & University of South Florida.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

Lyndsay Harris, +8 more
- 20 Nov 2007 - 
TL;DR: Thirteen categories of breast tumor markers were considered, six of which were new for the guideline, and certain multiparameter gene expression assays not all applications for these markers were supported, however.
Journal ArticleDOI

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Robert C. Bast, +11 more
- 13 Oct 1983 - 
TL;DR: Determination of CA 125 levels may aid in monitoring the response to treatment in patients with epithelial ovarian cancer, and rising or falling levels ofCA 125 correlated with progression or regression of disease in 42 of 45 instances.
Journal ArticleDOI

Reactivity of a monoclonal antibody with human ovarian carcinoma.

Robert C. Bast, +5 more
- 01 Nov 1981 - 
TL;DR: A murine monoclonal antibody (OC125) has been developed that reacts with each of six epithelial ovarian carcinoma cell lines and with cryopreserved tumor tissue from 12 of 20 ovarian cancer patients, but does not bind to a variety of nonmalignant tissues, including adult and fetal ovary.